BioSpace News Archive

Biomea Fusion, Inc. today announced that the first patient has been dosed in COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSIONTM System, in adult patients with relapsed or refractory acute leukemia.

ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1, at 4:30 p.m. ET to discuss third-quarter 2023 financial results and provide a general business update.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships.

HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, a global leader in radiology, to join QUANTI, Bayer’s Phase III clinical development program for gadoquatrane.

Lumen Bioscience—a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, announced it was awarded $16.2 million by the U.S. Department of Defense to advance LMN-201 through late-stage trials.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24th at 2:30 pm ET.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY) today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets.

Sonendo, Inc. announced its first Root Canal Forum for General Dentists, an educational and networking experience created by clinicians, for clinicians aimed at increasing adoption of the GentleWave System.

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.